Evidence map›Paper›PMID 42177198›Full record

ArticleNature communications2026

ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer.

Jessica E Gianopulos, Aidan Schutter, Stephanie Dobersch, Adrianne Wallace-Povirk, Sophie E Kogut, Andrea Doak, Pritha Chanana, Sabrina Ge, Luke Mangino, Naomi Yamamoto and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jessica E GianopulosHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Aidan SchutterHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0009-0006-6585-4308
Stephanie DoberschHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6633-4228
Adrianne Wallace-PovirkHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-9562-5892
Sophie E KogutProgram in Molecular and Cellular Biology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-4537-7584
Andrea DoakProgram in Molecular and Cellular Biology, University of Washington, Seattle, WA, USA.
Pritha ChananaGenomics and Bioinformatics Shared Resources, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-2255-8905
Sabrina GePrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-0242-753X
Luke ManginoHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Naomi YamamotoHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Liberalis D BoilaHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Monica Padilla-GalvezVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Justin HuiPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Nicole RhoadsPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-8331-5136
Robert J GiffordMRC-University of Glasgow Centre for Virus Research, Bearsden, Glasgow, UK.ORCID http://orcid.org/0000-0003-4028-9884
Kevin J CheungPublic Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6219-933X
Daniel Blanco-MeloVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-0256-5019
Faiyaz NottaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Sita KugelHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. skugel@fredhutch.org.ORCID http://orcid.org/0000-0001-7202-187X

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Exploring the epigenetic control of pancreatic cancer subtypesR37CA241472 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KUGEL, SITA · 2019 to 2025
$2.8M
Role of tumor cell cluster-induced signaling in breast cancer metastasisR37CA234488 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Kevin Jon Cheung · 2020 to 2026
$2.8M
Exploring the molecular mechanisms controlling CDK7i sensitivity in pancreas cancer.F32CA284723 · NCI · HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES · PI WALLACE-POVIRK, ADRIANNE · 2024 to 2025
$149k
Characterization of tumor-specific human endogenous retroviruses in clear cell Renal Cell CarcinomaF31CA306243 · NCI · FRED HUTCHINSON CANCER CENTER · PI Sophia Kogut · 2025 to 2026
$93k
NCI NIH HHS F31 CA306243NCI NIH HHS F32 CA284723NCI NIH HHS P30 CA015704NCI NIH HHS R37 CA234488NCI NIH HHS R37 CA241472
6 · The paper itself

Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) is characterized by two distinct transcriptional subtypes: classical and basal, which may interconvert. We show the KRAB-ZNF protein, ZNF274, correlates with PDAC subtype and regulates sensitivity to CDK7 inhibition by facilitating heterochromatin maintenance and gene suppression. We find ZNF274 loss drives a classical to basal transition, induces invasive protrusions and facilitates invasion capacity. We define two mechanistic arms to this regulation. ZNF274 directly suppresses ZEB1 expression. When ZNF274 is lost, ZEB1 facilitates acquisition of mesenchymal features, keratin gene expression, and susceptibility to CDK7 inhibition. Second, ZNF274 dampens expression of repetitive elements including human endogenous retroviruses (HERVs). HERV expression following ZNF274 loss induces a double stranded RNA response that reinforces the classical to basal subtype transition. Here, we show ZNF274 is an important epigenetic regulator of cellular plasticity and sensitivity to CDK7 inhibition, presenting a therapeutic liability of PDAC subtype transition that is actionable in the clinic.

Indexed as

Carcinoma, Pancreatic DuctalCyclin-Dependent KinasesDrug Resistance, NeoplasmPancreatic NeoplasmsProtein Kinase InhibitorsRepressor ProteinsAnimalsCell Line, TumorCell PlasticityCyclin-Dependent Kinase-Activating KinaseEndogenous RetrovirusesGene Expression Regulation, NeoplasticHumansZinc Finger E-box-Binding Homeobox 1Cyclin-Dependent Kinase-Activating KinaseCyclin-Dependent KinasesProtein Kinase InhibitorsRepressor ProteinsZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1

Identifiers

PMID42177198
PMCPMC13385776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.